Dr. Dreicer Discusses Using Abiraterone Acetate

Robert Dreicer, MD
Published: Tuesday, Apr 03, 2012



Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, explains that he began using the agent abiraterone acetate (Zytiga) shortly after its approval for metastatic castrate-resistant prostate cancer in April 2011.

The FDA indication for the compound was for patients that had already received docetaxel. Dreicer explains that he initially used the agent in this setting but has since moved its introduction into the first-line setting.

Dreicer notes that the agent performed similarly to clinical trials that demonstrated close to a 3 month increase in median overall survival. He added that although abiraterone acetate is not curative it is an important advance and a valuable addition to the prostate cancer armamentarium.
 


Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, explains that he began using the agent abiraterone acetate (Zytiga) shortly after its approval for metastatic castrate-resistant prostate cancer in April 2011.

The FDA indication for the compound was for patients that had already received docetaxel. Dreicer explains that he initially used the agent in this setting but has since moved its introduction into the first-line setting.

Dreicer notes that the agent performed similarly to clinical trials that demonstrated close to a 3 month increase in median overall survival. He added that although abiraterone acetate is not curative it is an important advance and a valuable addition to the prostate cancer armamentarium.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x